Jing Liu

Jing Liu

Auto-generated profile, based on publicly available information

Jing Liu

Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2022 in Cells
Verified
Journal Article
Open access
PDF file
zhiyong chenzhiyong chen
zhiyong chen
CZChi Zhang
Chi Zhang
XSXiaodan Song
Xiaodan Song
XCXiang Cui
Xiang Cui
JLJing Liu
Jing Liu
YGYun Guan
Yun Guan
The purinergic system plays an important role in pain transmission. Recent studies have suggested that activation of P2-purinergic receptors (P2Rs) may be involved in neuron-satellite glial cell (SGC) interactions in the dorsal root ganglia (DRG), but the details remain unclear. In DRG, P2X7R is selectively expressed in SGCs, which closely surround neurons, and is highly sensitive to 3’-O-(4-Benzoyl) benzoyl-ATP (BzATP). Using calcium imaging in intact mice to survey a large number of DRG neurons and SGCs, we examined how intra-ganglionic purinergic signaling initiated by BzATP affects neuronal activities in vivo. We developed GFAP-GCaMP6s and Pirt-GCaMP6s mice to express the genetically encoded calcium indicator GGCaM6s in SGCs and DRG neurons, respectively. The application of BzATP to the ganglion induced concentration-dependent activation of SGCs in GFAP-GCaMP6s mice. In Pirt-GCaMP6s mice, BzATP initially activated more large-size neurons than small-size ones. Both glial and neuronal responses to BzATP were blocked by A438079, a P2X7R-selective antagonist. Moreover, blockers to pannexin1 channels (probenecid) and P2X3R (A317491) also reduced the actions of BzATP, suggesting that P2X7R stimulation may induce the opening of pannexin1 channels, leading to paracrine ATP release, which could further excite neurons by acting on P2X3Rs. Importantly, BzATP increased the responses of small-size DRG neurons and wide-dynamic range spinal neurons to subsequent peripheral stimuli. Our findings suggest that intra-ganglionic purinergic signaling initiated by P2X7R activation could trigger SGC-neuron interaction in vivo and increase DRG neuron excitability.

2 February 2024 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
XCXiang Cui
Xiang Cui
JLJing Liu
Jing Liu
AUAnkit Uniyal
Ankit Uniyal
QXQian Xu
Qian Xu
CZChi Zhang
Chi Zhang
YGYun Guan
Yun Guan

15 November 2024 in Cells
Verified
Journal Article
Open access
PDF file
SHShao-Qiu Shao-Qiu He
Shao-Qiu Shao-Qiu He
CZChi Zhang
Chi Zhang
XWXuewei Wang
Xuewei Wang
QHQian Huang
Qian Huang
JLJing Liu
Jing Liu
YGYun Guan
Yun Guan
Background: The biologics derived from human amniotic membranes (AMs) demonstrate potential pain-inhibitory effects in clinical settings. However, the molecular basis underlying this therapeutic effect remains elusive. HC-HA/PTX3 is a unique water-soluble regenerative matrix that is purified from human AMs. We examined whether HC-HA/PTX3 can modulate the gene networks and transcriptional signatures in the dorsal root ganglia (DRG) neurons transmitting peripheral sensory inputs to the spinal cord. Methods: We conducted bulk RNA-sequencing (RNA-seq) of mouse DRG neurons after treating them with HC-HA/PTX3 (15 µg/mL) for 10 min and 24 h in culture. Differential gene expression analysis was performed using the limma package, and Gene Ontology (GO) and protein–protein interaction (PPI) analyses were conducted to identify the networks of pain-related genes. Western blotting and in vitro calcium imaging were used to examine the protein levels and signaling of pro-opiomelanocortin (POMC) in DRG neurons. Results: Compared to the vehicle-treated group, 24 h treatment with HC-HA/PTX3 induced 2047 differentially expressed genes (DEGs), which were centered on the ATPase activity, receptor–ligand activity, and extracellular matrix pathways. Importantly, PPI analysis revealed that over 50 of these DEGs are closely related to pain and analgesia. Notably, HC-HA/PTX3 increased the expression and signaling pathway of POMC, which may affect opioid analgesia. Conclusions: HC-HA/PTX3 induced profound changes in the gene expression in DRG neurons, centered around various neurochemical mechanisms associated with pain modulation. Our findings suggest that HC-HA/PTX3 may be an important biological active component in human AMs that partly underlies its pain inhibitory effect, presenting a new strategy for pain treatment.

17 December 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
AUAnkit Uniyal
Ankit Uniyal
NHNiyada Hin
Niyada Hin
CZChi Zhang
Chi Zhang
QXQian Xu
Qian Xu
QHQian Huang
Qian Huang
YGYun Guan
Yun Guan
The human Mas -related G protein–coupled receptor X1 (MrgprX1) represents a promising nonopioid analgesic target because of its selective expression in primary nociceptive sensory neurons. Positive allosteric modulators (PAMs) promote receptor signaling, depending on the availability of endogenous ligands, offering physiological selectivity over orthosteric agonists. We developed an orally bioavailable MrgprX1 PAM, 6-tert-butyl-5-(4-chlorophenyl)-4-(2-fluoro-6-(trifluoromethoxy)phenoxy)thieno[2,3-d]pyrimidine (BCFTP). BCFTP selectively potentiated the functional response of MrgprX1 in HEK293 cells, was metabolically stable, and demonstrated a favorable in vitro safety profile. BCFTP was orally bioavailable and distributed into the spinal cords of wild-type mice. BAM22, an endogenous ligand for MrgprX1, was up-regulated in the spinal cord after nerve injury in both wild-type and humanized MrgprX1 mice and was expressed in peptidergic and nonpeptidergic dorsal root ganglion neurons. Oral administration of BCFTP dose-dependently inhibited heat hyperalgesia and spontaneous pain-like behavior but not mechanical hypersensitivity after sciatic chronic constrictive injury (CCI) in MrgprX1 mice. BCFTP did not have analgesic effects in Mrgpr cluster knockout (Mrgpr −/− ) mice, indicating that the analgesic effects in MrgprX1 mice were MrgprX1 dependent. BCFTP enhanced BAM8-22–induced, MrgprX1-mediated reduction of C-fiber eEPSC amplitudes in spinal lamina II neurons, indicating inhibition of spinal nociceptive synaptic transmission. BCFTP did not induce tolerance or side effects, such as itch, sedation, and motor incoordination, and had no rewarding properties. The mRNAs encoding MrgprX1 and μ-opioid receptors were colocalized in human DRG neurons, and BCFTP synergistically enhanced morphine analgesia in CCI MrgprX1 mice. Our research suggests an approach for developing safer, orally bioavailable MrgprX1 PAM as a nonopioid therapy for neuropathic pain.

28 July 2026 in Pain
Verified
Journal Article
Closed access
LGLeo C. Guan
Leo C. Guan
JLJing Liu
Jing Liu
ZLZhaoli Luo
Zhaoli Luo
MJMichael Jiang
Michael Jiang
JZJun-Ming Zhang
Jun-Ming Zhang
QZQin Zheng
Qin Zheng
Spontaneous pain is a hallmark and debilitating feature of neuropathic pain, yet the mechanisms driving spontaneous pain remain poorly understood. Although abnormal spontaneous activity (SA) in primary sensory neurons has been observed after nerve injury, it remains unclear how such activity is organized across neuronal populations within the dorsal root ganglion (DRG) and how it relates to different pain components. Here, we used large-scale in vivo calcium imaging to examine spontaneous and stimulus-evoked activity in lumbar DRG neurons after spared-nerve injury (SNI). Spared-nerve injury significantly increased the incidence of single-neuron SA in DRG neurons. By combining functional imaging with retrograde labeling, we found that this activity arose not only from injured afferents (51.8%) but also from a substantial population of spared neurons (48.2%) within the same ganglion. Among spared neurons exhibiting spontaneous activity, nearly half (48.4%) showed no detectable responses to a broad panel of mechanical and thermal stimuli under our recording conditions, whereas most responsive neurons retained modality selectivity. Importantly, the incidence of single-neuron SA was positively associated with spontaneous pain-like behavior, but not with mechanical hypersensitivity, after SNI, supporting a direct link between SA of DRG neurons and spontaneous neuropathic pain. Together, these findings show that SA in the DRG is organized across both anatomical and functional dimensions, providing a framework for understanding how abnormal peripheral neuronal activity relates to spontaneous neuropathic pain.

24 August 2026 in Pain
Verified
Journal Article
Closed access
ZLZhaoli Luo
Zhaoli Luo
JLJing Liu
Jing Liu
XCXiang Cui
Xiang Cui
AUAnkit Uniyal
Ankit Uniyal
JWJieru Wan
Jieru Wan
YGYun Guan
Yun Guan
Spinal cord stimulation (SCS) is a clinically approved therapy for neuropathic pain (NP), yet a substantial subset of patients fails to respond or shows minimal efficacy, so-called nonresponders. It remains unclear how to resolve this SCS nonresponsiveness. Using a NP model induced by tibial-sparing nerve injury (SNI-t) in male rats, we investigated whether targeting the A3 adenosine receptor (A3AR), which is enriched in microglial cells, could convert nonresponders into responders. The dose–response relationship of 2-Cl-IB-MECA (a highly selective A3AR agonist) to inhibit mechanical hypersensitivity in male SNI-t rats after intraperitoneal injection was first established by measuring the paw withdrawal thresholds. Responders and nonresponders were classified based on the degree of reduction in mechanical hypersensitivity induced by conventional SCS (50 Hz, 0.2 milliseconds, 80% motor threshold, 30 minutes). A subtherapeutic dose of 2-Cl-IB-MECA (0.3 mg/kg, intraperitoneal) was subsequently combined with either acute or repeated SCS in nonresponders. Repeated SCS reduced microglial activation but produced limited analgesia in nonresponders. Subtherapeutic-dose 2-Cl-IB-MECA by itself induced minimal pain inhibition; however, when combined with SCS, it restored analgesic responses to both acute and repeated SCS. Notably, the pain reduction from repeated SCS was accompanied by a shift toward an anti-inflammatory microglial phenotype. These findings suggest that persistent microglial activation in male SNI-t rats may contribute to SCS nonresponsiveness, and that engaging A3AR signaling represents a promising strategy to convert nonresponders into SCS responders in NP conditions.